Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [And] European Academy of Otology and Neurotology|March 12, 2021
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical TrialCharlotte W Duinkerken, Vincent A de Weger, Wouter A Dreschler, et al.
The Journal of Clinical Investigation|November 3, 2007
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolismAntonius E van Herwaarden, Els Wagenaar, Cornelia M M van der Kruijssen, et al.
British Journal of Clinical Pharmacology|May 11, 2016
Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteersBart A W Jacobs, Maarten J Deenen, Dick Pluim, et al.
NPJ Breast Cancer|October 21, 2021
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal womenStacey E P Joosten, Marius Wellenstein, Rutger Koornstra, et al.
Nature Communications|November 13, 2014
Lysophospholipids secreted by splenic macrophages induce chemotherapy resistance via interference with the DNA damage responseJulia M Houthuijzen, Laura G M Daenen, Jeanine M L Roodhart, et al.
British Journal of Cancer|March 10, 2020
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancerRobin M J M van Geel, Emilie M J van Brummelen, Ferry A L M Eskens, et al.
The New England Journal of Medicine|November 8, 2023
Severe Immune-Related Enteritis after In Utero Exposure to PembrolizumabManuel A Baarslag, Joosje H Heimovaara, Jessica S W Borgers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated MelanomaAlaa Embaby, Sanne C F A Huijberts, Liqin Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer PatientsRichard D Baird, Annelot G J van Rossum, Mafalda Oliveira, et al.
Clinical Pharmacology and Therapeutics|April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyMirjam de With, Jonathan Knikman, Femke M de Man, et al.
Pageof 23